

Biodegradable stents are technically feasible and safe in Whipple Procedures.<sup>1</sup>

### USE of Biodegradable STENTS in Pancreaticoduodenectomy: Initial Experience.

Ibnouf Sulleman, Ahmed Elaffandi, and Hatem Khalaf. View all authors and affiliations. Volume 30, Issue 3. <https://doi.org/10.1177/1553350621123355>

<b>FAST</b> degrading stent	<b>12 days</b>
<b>MEDIUM</b> degrading stent	<b>20 days</b>
<b>SLOW</b> degrading stent	<b>11 weeks</b>

Biodegradation of the new biliary and pancreatic stents is reliable and in line with expected time.<sup>2</sup>

### New biliary and pancreatic biodegradable stent placement: a single-center, prospective, pilot study (with video).


Andrea Anderloni, MD, PhD, Alessandro Fugazza, MD, Luca Maroni, MD, PhD, Vittorio Ormando, MD, PhD, Roberta Maselli, MD, PhD, Silvia Carrara, MD, Annalisa Cappello, MD, Benedetto Mangiavillano, MD, Paolo Omodei, MD, Paoletta Preatoni, MD, Piera Alessia Galtieri, MD, Gaia Pellegatta, MD, Alessandro Repici, MD.



In 50 patients there was an encouragingly low rate of other pancreas-specific complications with the use of ARCHIMEDES in high-risk patients.<sup>3</sup>

### Novel biodegradable internal stent as a mitigation strategy in high-risk pancreaticojejunostomy: technical notes and preliminary results.


Michele Mazzola, Camillo Leonardo Bertoglio, Alessandro Giani, Andrea Zironda, Pietro Carnevali, Pietro Maria Lombardi, Paolo De Martini, Carmelo Magistro, Giovanni Ferrari.



Outcomes were very encouraging with NO POPFs or stent related complications as well as the ability to discharge all patients 7 day post-surgery.<sup>4</sup>

### USE of Biodegradable STENTS in Pancreaticoduodenectomy: Initial Experience.


Ibnouf Sulleman, Ahmed Elaffandi, and Hatem Khalaf. View all authors and affiliations. Volume 30, Issue 3. <https://doi.org/10.1177/1553350621123355>



Biodegradable stents can eliminate the complications associated with current plastic internal stents such as perforation, occlusions and retained stents.<sup>1,4</sup>

### Complications of temporary pancreatic stent insertion for pancreaticojejunal anastomosis during pancreaticoduodenectomy.

Michael J Levy, MD, Suresh Chari, MD, Douglas G Adler, MD, Jonathan E Clain, MD, Christopher J Gostout, MD, Gavin C Harewood, MD, Randall K Pearson, MD, Bret T Petersen, MD, Michael G Sarr, MD, Michael B Farnell, MD.



Costs associated with Grade B2 (9.9% Incidence), B3 (10.2% Incidence) and C (4.9% Incidence). POPF can be as costly as £75,000 per patient.<sup>5</sup>

### Clinical and economic validation of grade B postoperative pancreatic fistula subclassification.

Valentina Andreasi, MD, Stefano Partelli, MD, PhD, Paola M.V. Rancoita, PhD, Serena Mele, MD, Michele Mazza, MD, Dario La Fauci, MS, Nicolò Pecorelli, MD, Giovanni Guarneri, MD, Domenico Tamburrino, MD, PhD, Stefano Crippa, MD, PhD, Massimo Falconi, MD.




Using biodegradable a lower rate of POPF, PPH and major complications was found when a stent was used. Trans-anastomotic Stenting could be considered in all cases but especially in high-risk anastomosis. This may provide economic benefits to HPB settings globally.<sup>6</sup>

### AB03 Feasibility of biodegradable stents to reduce pancreatic fistula rates in high-risk anastomoses.

Dr. med. Laura-Ann Sahan, Dr. med. Omid Ghamar-Nejad, Dr. med. Rizky Widyaniingsih, Dr. med. Dr. habil. Gregor Alexander Stavrou. Department of General, Visceral- and Thoracic Surgery, Klinikum Saarbrücken, Germany.

ABSTRACT SUBMITTED TO ALPS 24- PUBLICATION PENDING



### References:

1. Suliaman, I., Elaffandi, A., Elmoghazy, W., & Khalaf, H. (2023). Use of biodegradable stents in pancreaticoduodenectomy: Initial experience. *Surgical Innovation*, 30(3), 340-348.
2. Anderloni, A., Fugazza, A., Maroni, L., Ormando, V., Maselli, R., Carrara, S., ... & Repici, A. (2020). New biliary and pancreatic biodegradable stent placement: a single-center, prospective, pilot study (with video). *Gastrointestinal Endoscopy*, 92(2), 405-411.
3. Zirona, A., Benedetti, A., Calcagno, P., Giani, A., Mazzola, M., & Ferrari, G. C. (2023). Novel Biodegradable Internal Stent as a Mitigation Strategy in High-risk Pancreaticojejunostomy: Update after 50 Cases. *HPB*, 25, S443.
4. Levy, M. J., Chari, S., Adler, D. G., Clain, J. E., Gostout, C. J., Harewood, G. C., ... & Farnell, M. B. (2004). Complications of temporary pancreatic stent insertion for pancreaticojejunal anastomosis during pancreaticoduodenectomy. *Gastrointestinal endoscopy*, 59(6), 719-724.
5. Andreasi, V., Partelli, S., Rancoita, P. M., Mele, S., Mazza, M., La Fauci, D., ... & Falconi, M. (2022). Clinical and economic validation of grade B postoperative pancreatic fistula subclassification. *Surgery*, 171(4), 846-853.
6. Dr. med. Laura-Ann Sahan, Dr. med. Omid Ghamar-Nejad, Dr. med. Rizky Widyaningsih, Dr. med. Dr. habil. Gregor Alexander Stavrou. Feasibility of biodegradable stents to reduce pancreatic fistula rates in high-risk anastomoses.

### Limitation Statement:

The information compiled in the Clinical Evolution of the data related to the biodegradable technology has some possible limitations, as it was not an exhaustive search but one that details key early investigator-led studies, that confirmed findings represented by the company and its CE approval related to the attributes of the stent. The findings of the studies, individually or collectively, may need additional evaluation in the form of more rigorous analysis and further future studies around economics, as well as multi-centre randomized studies to further evaluate the biodegradable technology against the limitations of the current standard of care for plastic and metal implants that require a 2nd surgery for removal.

**Items to include:** We suggest that you divide your limitations section into three steps: (1) identify the study limitations; (2) explain how they impact your study in detail; and (3) propose a direction for future studies and present alternatives.

This document will look to add more clinical data and information, as biodegradable products are further studied and utilized. Whilst there are limitations to the information, we look to build more randomized clinical data to further show increased patient care, healthcare cost savings, sustainability benefits as well as hospital resources and waiting list improvements.



PLEASE SCAN THE QR CODE TO ACCESS OUR DIGITAL LIBRARY TO VIEW BROCHURES, PUBLICATIONS, CASE REPORTS, VIDEOS AND MUCH MORE.